New single-cell study provides novel insights into gastric cancer

A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression. Highlights of the study include a link between multicellular communities and clinical outcomes as well as a potential new therapeutic target.   Gastric adenocarcinoma is one of the most lethal cancers worldwide due to inherent treatment resistance, but the cellular and molecular mechanisms involved in the progression from early...

DNA test could broaden access to cervical cancer screening

Rice University bioengineers have demonstrated a low-cost, point-of-care DNA test for HPV infections that could make cervical cancer screening more accessible in low- and middle-income countries where the disease kills more than 300,000 women each year.   HPV, a family of viruses, infects nearly everyone at some point in their lives, often without symptoms. But more than a dozen types of HPV can cause persistent infections that result in cervical cancer, which is preventable and curable if it...

New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers

Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression.   The study demonstrates that the loss of a cluster of interferon receptor (IFNR) genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability. This genomic feature may be used to help clinicians predict a tumor’s potential to become metastatic...

Blood test aids in predicting lung cancer mortality risk

A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying from lung cancer when combined with a personalized risk model.   According to new data, a blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify those at high risk of dying from lung cancer than the current U.S. Preventive Services Task Force (USPSTF) criteria.   These findings build upon previous MD Anderson...

Rice, Baylor developing ‘glyco-immune’ checkpoint inhibitor

Researchers from Rice University and Baylor College of Medicine are hoping a first-of-its-kind “glyco-immune” checkpoint inhibitor could be the key to stopping bone cancer metastasis for breast cancer survivors.   Breast cancer often migrates to other organs. As many as 40% of breast cancer survivors are diagnosed with metastatic cancer, sometimes years after their initial treatment. Bone metastasis is involved in more than two-thirds of those cases, and bone metastatic lesions are known to “seed”...

Brain has natural way to fight dementia, UTMB study suggests

Some people who have Alzheimer’s disease pathology never get dementia because they have a protective biological mechanism working in their favor, a new study suggests.   Researchers at the University of Texas Medical Branch studied postmortem brains and found that people who presented with brain pathology consistent with fully symptomatic Alzheimer’s disease—but not dementia—also had preserved autophagy, a physiological system that allows cells to recycle or eliminate junk and clutter.   “This is significant, because...

Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.   The OS was 7.4 months with fruquintinib versus 4.8 months in the placebo arm, while the median PFS was 3.7 months with fruquintinib compared to 1.8 months in the placebo arm. These results represent a statistically significant improvement relative to controls....

Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases

Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).   Findings from the Phase Ib cohort of the KRYSTAL-1 trial represent the first prospective data of anti-tumor activity from a KRAS G12C inhibitor in brain metastases, providing continued evidence of the drug’s efficacy.   The targeted...

Study unlocks potential breakthrough in Type 1 diabetes treatment

For the well over 700 million people around the globe living with Type 1 diabetes, getting a host immune system to tolerate the presence of implanted insulin-secreting cells could be life-changing.   Rice University bioengineer Omid Veiseh and collaborators identified new biomaterial formulations that could help turn the page on Type 1 diabetes treatment, opening the door to a more sustainable, long-term, self-regulating way to handle the disease.   To do so, they developed a new screening technique that involves...

Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease

A novel approach to administering intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center.   The study represents the first-in-human trial of concurrent IT and IV nivolumab (anti-PD-1) in melanoma patients with LMD. Across...

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives